Published January 28, 2014 by OSP
The Orphan Drug Act provided numerous incentives for pharmaceutical companies to treat rare diseases and conditions. However it strictly defined rareness by less than 200,000 patients. The US population increased by 82 million people between 1983 and 2013. The EU instead uses a proportion of the population to define rareness.